Clinical trial
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin…
NCT00235950 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00235950 |
|---|---|
| Title | Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease |
| Official title | A Multicentre Study Comparing the Efficacy of Rosuvastatin With Atorvastatin When Given for a Period of 16 Wks to Subjects With Coronary Heart Disease & a Previously Performed Percutaneous Coronary Intervention |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Heart Disease |
| Intervention type | Drug |
| Interventions | Rosuvastatin or atorvastatin or simvastatin and clopidogrel |
| Enrollment | 255 |
| Start date | Jan 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Oct 12, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: